Brian Skorney
Stock Analyst at Baird
(3.36)
# 1,001
Out of 4,984 analysts
115
Total ratings
43.9%
Success rate
5.86%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $14.70 | +253.74% | 4 | Aug 12, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Outperform | $30 → $35 | $17.05 | +105.28% | 12 | Jul 17, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $50.98 | +137.35% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $13.15 | +143.35% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $144.87 | +76.02% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $585.50 | +0.26% | 15 | Apr 30, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $50 → $55 | $73.14 | -24.80% | 5 | Feb 27, 2025 | |
| GILD Gilead Sciences | Maintains: Neutral | $95 → $100 | $112.26 | -10.92% | 3 | Feb 12, 2025 | |
| BNTC Benitec Biopharma | Initiates: Outperform | $30 | $13.70 | +118.98% | 1 | Dec 13, 2024 | |
| APLT Applied Therapeutics | Maintains: Outperform | $14 → $5 | $0.41 | +1,115.66% | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $7.54 | +165.25% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.13 | +505.33% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $10 | $3.82 | +161.78% | 2 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $274.71 | -21.74% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $157 → $180 | $142.73 | +26.11% | 4 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $5.36 | +422.39% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $62 | $34.20 | +81.29% | 4 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $9.03 | +331.89% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $36.70 | +71.66% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $387.15 | -16.05% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $15.11 | -33.82% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $2.90 | +9,210.34% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $4.26 | +40.85% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.67 | +17,864.07% | 3 | May 7, 2018 |
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $14.70
Upside: +253.74%
Sarepta Therapeutics
Jul 17, 2025
Maintains: Outperform
Price Target: $30 → $35
Current: $17.05
Upside: +105.28%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $50.98
Upside: +137.35%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $13.15
Upside: +143.35%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $144.87
Upside: +76.02%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $585.50
Upside: +0.26%
Mirum Pharmaceuticals
Feb 27, 2025
Maintains: Outperform
Price Target: $50 → $55
Current: $73.14
Upside: -24.80%
Gilead Sciences
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $112.26
Upside: -10.92%
Benitec Biopharma
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $13.70
Upside: +118.98%
Applied Therapeutics
Nov 29, 2024
Maintains: Outperform
Price Target: $14 → $5
Current: $0.41
Upside: +1,115.66%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $7.54
Upside: +165.25%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $4.13
Upside: +505.33%
Oct 23, 2024
Maintains: Outperform
Price Target: $32 → $10
Current: $3.82
Upside: +161.78%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $274.71
Upside: -21.74%
Aug 2, 2024
Maintains: Outperform
Price Target: $157 → $180
Current: $142.73
Upside: +26.11%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $5.36
Upside: +422.39%
May 23, 2024
Maintains: Outperform
Price Target: $52 → $62
Current: $34.20
Upside: +81.29%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $9.03
Upside: +331.89%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $36.70
Upside: +71.66%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $387.15
Upside: -16.05%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $15.11
Upside: -33.82%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $2.90
Upside: +9,210.34%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $4.26
Upside: +40.85%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.67
Upside: +17,864.07%